Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition

Jahn, Jennifer E.; Best, D. Hunter; Coleman, William B.

doi:10.1016/j.yexmp.2010.09.001

Cited by 11 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SYT13 resides on human chromosome 11p11.2 and encodes a predicted single‐pass 47‐kDa transmembrane protein. The synaptotagmin family includes proteins that mediate membrane trafficking. Unlike other synaptotagmins, SYT13 lacks the extracellular N‐terminus and critical residues required for calcium binding.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer

Kanda

Shimizu

Tanaka

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Unlike other synaptotagmins, SYT13 lacks the extracellular N‐terminus and critical residues required for calcium binding. These distinctive characteristics, as well as its widespread distribution in brain, indicate that SYT13 is involved in constitutive vesicular transport, but little is known about its role in cancer.…”

Section: Discussionmentioning

confidence: 99%

Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer

Kanda

Shimizu

Tanaka

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Identification of the serial differential expression of genes from normal tissues to primary tumors to metastases indicated that various genes, including PMP22, SYT13 and SERPINA10, are associated with the progression of small bowel neuroendocrine tumors (36). Jahn et al demonstrated that the human SYT13 gene acts as a liver tumor suppressor gene and its function may be mediated through pathways implicated in mesenchymal-to-epithelial transition (37). Importantly, Zhu et al observed differential expression of SYT13 between left- and right-sided colon carcinomas by microarray analysis (38), suggesting the possible involvement of SYT13 in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells

Zhang

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

The treatment of colorectal cancer is currently hampered by the lack of early detection technology. The identification of molecular biomarkers for colorectal cancer is crucial for improving prognosis. Synaptotagmin (SYT) 13 has been reported to be associated with several human tumors, but its role in colorectal cancer remains elusive. In the present study, immunohistochemistry was utilized to detect the expression of SYT13 in colorectal cancer tissues and cells. MTT, colony formation, wound healing and Transwell assays were conducted to evaluate the effect of SYT13 knockdown on the biological behavior of RKO and HCT116 cells. Cell apoptosis and cell cycle profiles were detected by FACS. A mouse xenograft model was constructed to investigate the effect of SYT13 on colorectal cancer in vivo. The results indicated that SYT13 was upregulated in colorectal tumor tissues compared with paracancerous tissues. Silencing of SYT13 inhibited the proliferation, colony formation, migration and invasion ability of RKO and HCT116 cells. Moreover, SYT13 knockdown arrested the cell cycle in the G2 phase, thus inducing cell apoptosis. The in vivo experiments also demonstrated the inhibitory effect of SYT13 on tumor growth. In conclusion, the present study demonstrated that SYT13 may act as a promoter in the development and progression of colorectal cancer and, therefore, may be of value as a target for the development of novel treatment strategies.

show abstract

“…Previous studies have shown that the SYT family genes regulate proliferation, invasion, and metastasis in several cancer cells in addition to their roles in neuronal cells [32][33][34][35]. Of SYT family, SYT12 is detected as a biomarker of papillary thyroid cancer [10], but the molecular biologic function of SYT12 in other cancer cells and the interactions between SYT12 and cancer-associated signaling pathways remain unknown.…”

Section: Discussionmentioning

confidence: 99%

SYT12 plays a critical role in oral cancer and may be a novel therapeutic target

Eizuka¹,

Nakashima²,

Oka³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Synaptotagmin12 (SYT12) has been well characterized as the regulator of transmitter release in the nervous system, however the relevance and molecular mechanisms of SYT12 in oral squamous cell carcinoma (OSCC) are not understood. In the current study, we investigated the expression of SYT12 and its molecular biological functions in OSCC by quantitative reverse transcriptase polymerase chain reaction, immunoblot analysis, and immunohistochemistry. SYT12 were up-regulated significantly in OSCC-derived cell lines and primary OSCC tissue compared with the normal counterparts (P<0.05) and the SYT12 expression levels were correlated significantly with clinical indicators, such as the primary tumoral size, lymph node metastasis, and TNM stage (P<0.05). SYT12 knockdown OSCC cells showed depressed cellular proliferation, migration, and invasion with cell cycle arrest at G1 phase. Surprisingly, we found increased calcium/calmodulin-dependent protein kinase 2 (CAMK2) inhibitor 1 (CAMK2N1) and decreased CAMK2-phosphorylation in the knockdown cells. Furthermore, treatment with L-3, 4-dihydroxyphenylalanine (L-dopa), a drug approved for Parkinson's disease, led to down-regulation of SYT12 and similar phenotypes to SYT12 knockdown cells. Taken together, we concluded that SYT12 plays a significant role in OSCC progression via CAMK2N1 and CAMK2, and that L-dopa would be a new drug for OSCC treatment through the SYT12 expression.

show abstract

Exogenous expression of synaptotagmin XIII suppresses the neoplastic phenotype of a rat liver tumor cell line through molecular pathways related to mesenchymal to epithelial transition

Cited by 11 publications

References 25 publications

Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer

Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer

Silencing of synaptotagmin 13 inhibits tumor growth through suppressing proliferation and promoting apoptosis of colorectal cancer cells

SYT12 plays a critical role in oral cancer and may be a novel therapeutic target

Contact Info

Product

Resources

About